Catalyst (CPRX) Director Daniel Curran Cancels 63,583 RSUs/Options

What Happened
Daniel J. Curran, a Director of Catalyst Pharmaceuticals (CPRX), reported dispositions of derivative awards on 2026-07-15. The Form 4 shows three dispositions to the issuer: 40,000; 18,115; and 5,468 units — a total of 63,583 derivative awards — reported at $0.00 (derivative disposition). Footnotes state these awards (RSUs and options) vested in full and were cancelled and converted into cash in connection with the Merger; the cash payout is calculated under the filing’s formula (see Key Details). The reported $0.00 per-unit reflects conversion/settlement to the issuer rather than an open-market stock sale.

Key Details

• Transaction date: 2026-07-15. Form filed: 2026-07-17 (timely filing).
• Reported dispositions: 40,000; 18,115; and 5,468 derivative units (total 63,583). Reported price: $0.00 (derivative disposition to issuer).
• Footnotes summarized:
  • F1: Each RSU represents a contingent right to one share.
  • F2: Options were cancelled and converted to a cash payment equal to (excess of $31.50 over the option strike) × number of option shares.
  • F3: RSUs were cancelled and converted to a cash payment based on $31.50 per share (see filing).
  • F4: All reported Options/RSUs vested in full at the Merger.
• Exact cash amounts and post-transaction withholding are not shown on the Form 4 and depend on option strike prices, tax withholding and authorized deductions.
• Shares owned after the transactions are not specified in the provided filing excerpt.

Context
These were corporate-triggered settlements tied to a merger (derivative awards cancelled and paid in cash), not open-market sales of common stock. Such cancellations/settlements are routine in M&A and reflect contract terms rather than an insider choosing to sell shares on the market. The filing does not by itself indicate insider sentiment about the company’s future.